Loading clinical trials...
Loading clinical trials...
This study will assess at Week 16 the efficacy and safety of AIN457 at different doses in patients with active RA despite stable MTX therapy. Treatment will continue up to Week 48 with a safety follow...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT07627542 · Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), and more
NCT07632872 · Rheumatoid Arthritis (RA), Rheumatoid Arthritis
NCT06733935 · Systemic Sclerosis, Idiopathic Inflammatory Myopathies, and more
NCT07455578 · Autoimmune Diseases, Rheumatoid Arthritis (RA), and more
NCT07171983 · Rheumatoid Arthritis
Novartis Investigative Site
Mesa, Arizona
Novartis Investigative Site
Peoria, Arizona
Novartis Investigative Site
Little Rock, Arkansas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions